Avalyn Pharma (NASDAQ:AVLN) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Avalyn Pharma (NASDAQ:AVLN) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Other analysts have also recently issued reports about the stock. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research note on Thursday. They issued a “sell (d+)” rating for the company. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company. Evercore started coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective for the company. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Finally, Guggenheim started coverage on Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $80.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Price Performance

Shares of NASDAQ:AVLN opened at $38.25 on Friday. The company’s 50-day simple moving average is $30.35. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a 1 year low of $24.15 and a 1 year high of $39.99. The firm has a market cap of $1.70 billion and a price-to-earnings ratio of -1.75.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. On average, analysts expect that Avalyn Pharma will post -3.81 EPS for the current year.

Hedge Funds Weigh In On Avalyn Pharma

A hedge fund recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp acquired a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma at the end of the most recent quarter.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.